			Home About us Contact

Ageing Male (ageing + male)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Hypogonadism-related symptoms: development and evaluation of an empirically derived self-rating instrument (HRS ,Hypogonadism Related Symptom Scale')

ANDROLOGIA, Issue 5 2009
J. Wiltink
Summary While self-report screening instruments are highly sensitive to hypogonadism in the ageing male, they have lacked specificity as evidenced by low or absent correlations with testosterone. The purpose of this paper was to develop an economical and specific screening instrument for identifying hypogonadal ageing men. Based on a comprehensive study of physical, somatoform and affective complaints, sexual behaviour and function and hormonal parameters of 263 outpatients aged 40 years and above (M = 56.2; 40,84 years) recruited from six andrological outpatient departments in Germany, we identified those items correlating significantly with testosterone. By factor analyses, five factors were identified: ,reduced activity', ,dissatisfaction with sexual function', ,negative self-concept of physical fitness', ,reduced sexual desire' and ,hot flushes'. The corresponding scales were reliable and only moderately inter-correlated. Consistent correlations were found with the level of testosterone, ageing male scales (Androgen Deficiency in the Aging Male, Aging Male Survey), specific affective, somatoform and sexual functioning scales and potential determinants of low testosterone (body mass index, physical inactivity, etc.). While further validation is needed, the new Hypogonadism Related Symptoms Scale appears to be a promising hypogonadism screening tool. [source]

Review article Testosterone therapy in the ageing male: what about the prostate?

ANDROLOGIA, Issue 6 2004
D. Schultheiss
Summary. The concerns about testosterone therapy in ageing men with late-onset hypogonadism mainly address the risk of prostatic disease, i.e. either benign prostatic hyperplasia (BPH) or prostate cancer (PCa). Both conditions are highly dependent on androgen action and recent clinical data on the cancer-preventive effect of the 5, -reductase inhibitor finasteride have supported the possible role of androgens in PCa. However, the clinical data especially on the long-term effects of exogenous androgen substitution in regard to prostate safety are nonconclusive in many respects. As sufficient clinical studies on these risks will not be available in the near future, the approach of testosterone therapy towards prostate complications should be kept on a safe but practical basis. This review includes some recommendations in regard to testosterone therapy and prostate monitoring in patients with BPH and bladder outlet obstruction, with previous history of curative treatment for PCa or with prostatic intraepithelial neoplasia. [source]

Measurement of testosterone in the diagnosis of hypogonadism in the ageing male

CLINICAL ENDOCRINOLOGY, Issue 4 2008
M. J. Wheeler
Summary Many males in their old age demonstrate symptoms consistent with hypogonadism. With the introduction of new and more convenient methods of testosterone replacement treatment of these males is more practical. The diagnosis of hypogonadism in the older male has been controversial with some clinicians suggesting that symptoms should be treated without due reliance on testosterone concentrations. However, most professional bodies have proposed that a low testosterone concentration should be part of the diagnosis. This is, in turn, reliant on the testosterone measurement being reliable and read against an appropriate reference range. This review looks at the factors that can influence the interpretation of testosterone results for the ageing male. [source]